View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar Pulmonológiai Klinika Budapest Diós árok 1/C 1125
Open access

A molekuláris célzott terápia – a lehetőségek bővülésével – egyre inkább szerephez jut a tüdőrákos betegek ellátásában. Ezzel együtt rendkívül fontossá vált a daganatnak nemcsak a pontos szövettani tipizálása, hanem molekuláris jegyeinek feltérképezése is. A rutin klinikai gyakorlatban citotoxikus kezelésnél betegszelekció céljából prediktív szöveti markereket még nem alkalmazunk, azonban egyre bővülnek azok a kutatási eredmények, amelyek segíthetik az onkológusokat abban, hogy egyszer majd a betegeiket egyénre szabott kemoterápiában részesíthessék. Különösen megnőhet ennek jelentősége akkor, amikor a beteg életkora, általános állapota és/vagy társbetegségei miatt a kemoterápiának még az alkalmazhatósága is megkérdőjeleződik. A tüdőrák molekuláris célzott terápiája manapság elsősorban az adenocarcinomában szenvedőknek ad reményt, az intenzív kutatások eredményeképpen azonban már körvonalazódnak további ígéretes terápiás célpontok. Napjainkban az onkopulmonológia forrongó korszakának lehetünk szemtanúi, ami minden nehézsége ellenére a tüdőrákban szenvedők és kezelőorvosaik számára egyaránt reményekkel szolgál. Orv. Hetil., 2012, 153, 909–916.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Strausz, J., Csoma, Zs., Kovács, G., et al.: Korányi Bulletin. [Korányi Bulletin.], 2011, 1, 16. [Hungarian]

    Kovács G. , 'Korányi Bulletin ' (2011 ) 1 Korányi Bulletin : 16 -.

  • Zheng, Z., Chen, T., Li, X., et al.: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med., 2007, 356, 800–808.

    Li X. , 'DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer ' (2007 ) 356 N. Engl. J. Med. : 800 -808.

    • Search Google Scholar
  • Martin, L. P., Hamilton, T. C., Schilder, R. J.: Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res., 2008, 14, 1291–1295.

    Schilder R. J. , 'Platinum resistance: the role of DNA repair pathways ' (2008 ) 14 Clin. Cancer Res. : 1291 -1295.

    • Search Google Scholar
  • Okuda, K., Sasaki, H., Dumontet, C., et al.: Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer, 2008, 62, 105–112.

    Dumontet C. , 'Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer ' (2008 ) 62 Lung Cancer : 105 -112.

    • Search Google Scholar
  • Sun, J. M., Han, J., Ahn, J. S., et al.: Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J. Thorac. Oncol., 2011, 6, 1392–1399.

    Ahn J. S. , 'Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy ' (2011 ) 6 J. Thorac. Oncol. : 1392 -1399.

    • Search Google Scholar
  • Bepler, G., Sommers, K. E., Cantor, A., et al.: Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J. Thorac. Oncol., 2008, 3, 1112–1118.

    Cantor A. , 'Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer ' (2008 ) 3 J. Thorac. Oncol. : 1112 -1118.

    • Search Google Scholar
  • Avien-Ronen, S., Blackhall, F. H., Shepherd, F. A., et al.: K-ras mutations in non-small-cell lung carcinoma: a review. Clin. Lung Cancer, 2006, 8, 30–38.

    Shepherd F. A. , 'K-ras mutations in non-small-cell lung carcinoma: a review ' (2006 ) 8 Clin. Lung Cancer : 30 -38.

    • Search Google Scholar
  • Yoshimasu, T., Oura, S., Ohta, F., et al.: Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer. J. Thorac. Oncol., 2011, 6, 1658–1662.

    Ohta F. , 'Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer ' (2011 ) 6 J. Thorac. Oncol. : 1658 -1662.

    • Search Google Scholar
  • Camidge, D. R., Kono, S. A., Lu, X., et al.: Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J. Thorac. Oncol., 2011, 6, 774–780.

    Lu X. , 'Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed ' (2011 ) 6 J. Thorac. Oncol. : 774 -780.

    • Search Google Scholar
  • Simon, G. R., Schell, M. J., Begum, M., et al.: Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis. Cancer, 2011, 112, 2021–2029.

    Begum M. , 'Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis ' (2011 ) 112 Cancer : 2021 -2029.

    • Search Google Scholar
  • Vilmar, A., Garcia-Foncillas, J., Huarriz, M., et al.: RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. Lung Cancer, 2012, 75, 306–312. [Available online 13 October 2011]

    Huarriz M. , 'RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC ' (2012 ) 75 Lung Cancer : 306 -312.

    • Search Google Scholar
  • Sandler, A., Gray, R., Perry, M. C., et al.: Paclitaxel-carboplatin alone or with bevacuzimab for non-small-cell ling cancer. N. Engl. J. Med., 2006, 355, 2542–2550.

    Perry M. C. , 'Paclitaxel-carboplatin alone or with bevacuzimab for non-small-cell ling cancer ' (2006 ) 355 N. Engl. J. Med. : 2542 -2550.

    • Search Google Scholar
  • Pirker, R., Pereira, J. R., Szczesna, A., et al.: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, 2009, 373, 1525–1531.

    Szczesna A. , 'Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial ' (2009 ) 373 Lancet : 1525 -1531.

    • Search Google Scholar
  • O’Byrne, K. J., Gatzemeier, U., Bondarenko, I., et al.: Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol., 2011, 12, 795–805.

    Bondarenko I. , 'Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study ' (2011 ) 12 Lancet Oncol. : 795 -805.

    • Search Google Scholar
  • Schwab, R., Pinter, F., Moldvay, J., et al.: Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib. J. Clin. Oncol., 2005, 23, 7736–7738.

    Moldvay J. , 'Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib ' (2005 ) 23 J. Clin. Oncol. : 7736 -7738.

    • Search Google Scholar
  • Lynch, T. J., Bell, D. W., Sordella, R., et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2004, 350, 2129–2139.

    Sordella R. , 'Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib ' (2004 ) 350 N. Engl. J. Med. : 2129 -2139.

    • Search Google Scholar
  • Paez, J. G., Janne, P. A., Lee, J. C., et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304, 1497–1500.

    Lee J. C. , 'EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy ' (2004 ) 304 Science : 1497 -1500.

    • Search Google Scholar
  • Riely, G. J., Marks, J., Pao, W.: KRAS mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc., 2009, 6, 201–205.

    Pao W. , 'KRAS mutations in non-small cell lung cancer ' (2009 ) 6 Proc. Am. Thorac. Soc. : 201 -205.

    • Search Google Scholar
  • Shigematsu, H., Lin, L., Takahashi, T., et al.: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst., 2005, 97, 339–346.

    Takahashi T. , 'Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers ' (2005 ) 97 J. Natl. Cancer Inst. : 339 -346.

    • Search Google Scholar
  • Pinter, F., Papay, J., Almasi, A., et al.: Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J. Mol. Diagn., 2008, 10, 160–168.

    Almasi A. , 'Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry ' (2008 ) 10 J. Mol. Diagn. : 160 -168.

    • Search Google Scholar
  • Cappuzzo, F., Jänne, P. A., Skokan, M., et al.: MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann. Oncol., 2009, 20, 298–304.

    Skokan M. , 'MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients ' (2009 ) 20 Ann. Oncol. : 298 -304.

    • Search Google Scholar
  • Becker, A., Crombag, L., Heideman, D. A. M., et al.: Retreatment with erlotinib. Regain of EGFR-TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur. J. Cancer, 2011, 47, 2603–2606.

    Heideman D. A. M. , 'Retreatment with erlotinib. Regain of EGFR-TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment ' (2011 ) 47 Eur. J. Cancer : 2603 -2606.

    • Search Google Scholar
  • Watanabe, S., Tanaka, J., Ota, T.: Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer, 2011, 11, 1.

    Ota T. , 'Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis ' (2011 ) 11 BMC Cancer : 1 -.

    • Search Google Scholar
  • Just, P. A., Cazes, A., Audebourg, A., et al.: Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: A comprehensive study of Caucasian non-smokers. Lung Cancer, 2011 Dec 6. [Epub ahead of print]

  • Shaw, A. T., Yeap, B. Y., Solomon, B. J., et al.: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol., 2011, 12, 1004–1012.

    Solomon B. J. , 'Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis ' (2011 ) 12 Lancet Oncol. : 1004 -1012.

    • Search Google Scholar
  • www.ClinicalTrials.gov